Cargando…

Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment

OBJECTIVE: Stimulants are first-line pharmacotherapy for individuals with attention-deficit hyperactivity disorder. However, disparities in drug coverage may contribute to inequitable treatment access. In January 2018, the government of Ontario, Canada, implemented a publicly-funded program (OHIP+)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antoniou, Tony, McCormack, Daniel, Kitchen, Sophie, Pajer, Kathleen, Gardner, William, Lunsky, Yona, Penner, Melanie, Tadrous, Mina, Mamdani, Muhammad, Juurlink, David N., Gomes, Tara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590092/ https://www.ncbi.nlm.nih.gov/pubmed/37016841 http://dx.doi.org/10.1177/07067437231166836

Ejemplares similares

Impact of a publicly-funded pharmacare program policy on benzodiazepine dispensing among children and youth: a population-based natural experiment
por: Antoniou, Tony, et al.
Publicado: (2023)

Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study
por: Antoniou, Tony, et al.
Publicado: (2023)

Adherence to antipsychotic laboratory monitoring guidelines in children and youth: a population-based study
por: Antoniou, Tony, et al.
Publicado: (2023)

The Risk of Ventricular Dysrhythmia or Sudden Death in Patients Receiving Serotonin Reuptake Inhibitors With Methadone: A Population-Based Study
por: Antoniou, Tony, et al.
Publicado: (2022)

Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study
por: Martins, Diana, et al.
Publicado: (2020)

Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults
por: Black, Cody D., et al.
Publicado: (2018)

Varenicline and Risk of Self-Harm: A Nested Case-Control Study
por: Tadrous, Mina, et al.
Publicado: (2016)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
por: Hajizadeh, Mohammad, et al.
Publicado: (2019)

Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population‐based time–series analysis
por: Antoniou, Tony, et al.
Publicado: (2021)

National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare"
por: Rawson, Nigel S. B.
Publicado: (2020)

Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study
por: Tadrous, Mina, et al.
Publicado: (2018)

Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population‐based propensity‐score matched cohort study
por: Gomes, Tara, et al.
Publicado: (2022)

Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2022)

Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis
por: Gomes, Tara, et al.
Publicado: (2021)

A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride
por: Antoniou, Tony, et al.
Publicado: (2018)

Understanding the Battle for Universal Pharmacare in Canada Comment on "Universal Pharmacare in Canada"
por: Gagnon, Marc-André
Publicado: (2020)

Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada
por: Fenna, Jennifer, et al.
Publicado: (2021)

The Burden of Opioid-Related Mortality in the United States
por: Gomes, Tara, et al.
Publicado: (2018)

Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities
por: Lunsky, Yona, et al.
Publicado: (2017)

Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study
por: Gomes, Tara, et al.
Publicado: (2019)

Trends in Opioid Toxicity–Related Deaths in the US Before and After the Start of the COVID-19 Pandemic, 2011-2021
por: Gomes, Tara, et al.
Publicado: (2023)

The Challenges of Canadian Pharmacare Are More Complicated Than Acknowledged Comment on "Universal Pharmacare in Canada"
por: Acri née Lybecker, Kristina M. L.
Publicado: (2020)

The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis
por: Boone, Charlotte G., et al.
Publicado: (2021)

The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men
por: Piszczek, Jolanta, et al.
Publicado: (2014)

Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants
por: Gao, Lulu, et al.
Publicado: (2017)

Measuring the Burden of Opioid-related Mortality in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults
por: Tadrous, Mina, et al.
Publicado: (2021)

Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario
por: Gomes, Tara, et al.
Publicado: (2022)

Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare
por: Brandt, Jaden, et al.
Publicado: (2018)

Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2019)

Separated at Birth: The Politics of Pharmacare for All in Canada and Medicare for All in the United States Comment on "Universal Pharmacare in Canada"
por: Tuohy, Carolyn Hughes
Publicado: (2020)

Statins and the Risk of Herpes Zoster: A Population-Based Cohort Study
por: Antoniou, Tony, et al.
Publicado: (2014)

Safety of valproic acid in patients with chronic obstructive pulmonary disease: a population-based cohort study
por: Antoniou, Tony, et al.
Publicado: (2015)

Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study
por: Pasricha, Sachin V., et al.
Publicado: (2018)

Changing patterns of opioid initiation for pain management in Ontario, Canada: A population-based cross-sectional study
por: Gomes, Tara, et al.
Publicado: (2022)

Introduction of publicly funded pharmacare and socioeconomic disparities in glycemic management in children and youth with type 1 diabetes in Ontario, Canada: a population-based trend analysis
por: Giruparajah, Mohana, et al.
Publicado: (2022)

Greater than the Sum: Applying Daily-Dose Equivalents to Antipsychotic Prescription Claims to Study Real-World Effects
por: Hayes, Kaleen N., et al.
Publicado: (2021)

Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis
por: Chang, Ann, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4okltonkd27u7ciqbhdvdqrd2m